We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Talaris Therapeutics Inc | NASDAQ:TALS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.72 | 2.63 | 2.78 | 0 | 01:00:00 |
The accepted oral presentation includes data on the company’s analysis of peripheral blood chimerism as a biomarker for transplantation tolerance. Phase 2 data indicate that one, three, six, and 12-month chimerism levels are highly correlated with each other and increasingly predictive over time of the ability to withdraw immunosuppression at one year, suggesting that whole blood and T-cell chimerism could be a valuable surrogate marker of the ability to discontinue immunosuppression at one year without rejection of the transplanted organ.
In addition, a poster will report on the long-term follow-up of the company’s Phase 2 trial in living donor kidney transplant recipients. Among the 37 subjects administered FCR001, 26 displayed durable chimerism allowing for full withdrawal of immunosuppression, and updated data show that all stable chimeric subjects remain rejection-free with a minimum follow-up of four years and the longest follow-up of almost 12 years.
The company will also be delivering two invited presentations and two sponsored virtual lounge sessions.
INVITED ORAL PRESENTATIONS
Title: “Cellular Therapy to Modify the Recipient Immune System”Presenter: Suzanne Ildstad, Talaris TherapeuticsSession Title: New Approaches to Tackling AlloimmunityDate & Time: Friday, June 4, 3:00 p.m. ET
Title: “Peripheral Blood Hematopoietic Chimerism: A Robust Biomarker for Transplantation Tolerance”Session Title: What’s Hot and What’s NewDate & Time: Wednesday, June 9, 12:25 p.m. ET
ORAL ABSTRACT PRESENTATION
Title: “Peripheral Blood Hematopoietic Chimerism: A Robust Biomarker for Transplantation Tolerance”Presenter: David Tollerud, Talaris TherapeuticsSession Title: Biomarkers, Immune Assessment and Clinical Outcomes - IAbstract: 18Date & Time: Saturday, June 5, 5:05 p.m. ET
POSTER PRESENTATION
Title: “Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients”Presenter: Joe Leventhal, M.D., Ph.D., Northwestern Memorial Hospital Session Title: Tolerance: Clinical StudiesAbstract: 685
SPONSOR CONNECT SESSIONS
Session 1: Sunday, June 6, 11:30 a.m. - 12:00 p.m. ETPresenter: Suzanne Ildstad, Talaris Therapeutics Title: FCR001 Investigational Cellular Therapy in Living Donor Kidney Transplantation
Session 2: Monday, June 7, 11:30 a.m. - 12:00 p.m. ETPresenter: Nancy Krieger, Talaris Therapeutics Title: FCR001 Investigational Cellular Therapy in Living Donor Kidney Transplantation
About Talaris TherapeuticsTalaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.
Media ContactLisa RaffenspergerTen Bridge Communicationslisa@tenbridgecommunications.com(617) 903-8783
Investor ContactChris BrinzeyWestwicke, an ICR Companychris.brinzey@westwicke.com(339) 970-2843
1 Year Talaris Therapeutics Chart |
1 Month Talaris Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions